Drawing for LEPETIT

USPTO serial 71616913

LEPETIT

Reviewed by CopyMark Law Group

Reg. 0596521Status 900
Filing date
Status date
Registration date
Oct 5, 1954
Examiner
—
Law office
—

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LEPETIT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
018ANTI-INFLUENZAL, INTESTINAL ANTISEPTIC, PERIPHERAL VASOCONSTRICTOR, HYPOTENSIVE, PARENTERAL CALCIUM THERAPY, ANTICOAGULANT, NEUROMUSCULAR RELAXANTS, ANTI-HISTAMINIC, ANTI-AMOEBIC, ANTI-EPILEPTIC AND ANTICONVULSANT, CHEMIO-THERAPEUTIC ANTISEPTIC, ANTIRHEUMATIC, URINARY AND INTESTINAL ANTISEPTIC, IODINE THERAPY, FACTOR OF CELLULAR REGENERATION, ANTI-MALARIAL, RENAL EXCRETION RETARDANT, ANTINEURALGIC, ANTIRHEUMATIC, SEDATIVE AND HYPNOTIC, ANTIPURETIC, ANTINEURALGIC, ANTIRHEUMATIC, DIURETIC, DIGESTIVE, DIASTASIC, STIMULANT OF THE RESPIRATORY CENTERS, ANTIHAEMORRHOIDAL, NEURO-MUSCULAR TONIC, THYROID ANTAGONIST, URINARY, INTESTINAL AND BILIARY ANTISEPTIC, DIETARY SUPPLEMENTS, ANTIACID, LAXATIVE, VITAMINIC, ANTISPASMODIC, EXPECTORANTS, TREATMENT OF COLDS, COUGHS AND OTHER BRONCHIAL AND PULMONARY AFFECTIONS, MILK MODIFIERS, TREATMENT OF HEART DISEASES, TREATMENT OF UTERINE DISORDERS, TREATMENT OF SKIN DISEASES, COUNTERIRRITANTS, AND TREATMENT OF ANEMIASEXPIRED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 10, 1995EXRGEXPIRED SEC. 9—
Oct 5, 1974REN1REGISTERED AND RENEWED (FIRST RENEWAL - 20 YRS)—

Frequently asked questions

Related guidance